Genomic Expression has advanced to the semifinals of the XPRIZE
Genomic Expression leveraged its OneRNA® platform to massively scale COVID-19 testing using Next Generation Sequencing.
PRESENTING TODAYat 11.45 am - 12.40 pm at the Massachusetts Innovation Network's September Pitch - Please Register here
Background
Genomic Expression is an RNA diagnostic company in infectious disease, COVID-19 and oncology.
Genomic Expression developed proprietary RNA sequencing technology that enables sequencing of real clinical samples and clinical interpretation of data. The company filed for CLIA certification in December 2019 in anticipation of launching OneRNA in 2020.
Then in February 2020, it became clear that COVID-19 testing was creating a bottleneck. Genomic Expression validated its own COVID-19 PCR test securing its own reagent supply and filed an FDA EUA to assist in providing access to testing.
This COVID-19 PCR test is commercially available. For more information click here
Genomic Expression started working on leveraging its RNA sequencing technology to massively scale COVID-19 testing to hundreds of thousands of tests/runs using Illumina's sequencing platform. By providing a kit to all labs with a sequencing machine, this technology can be scaled to screen 20% of the world’s population in one week.
In September, the company filed with the XPRIZE and, within weeks, it was announced that it is now in the semifinals.
About the XPRIZE
The XPRIZE mission is to bring about "radical breakthroughs for the benefit of humanity" through incentivized competition. It fosters high-profile competitions to motivate individuals, companies and organizations across all disciplines to develop innovative ideas and technologies that help solve the world's grand challenges. Their Board of Trustees include James Cameron, Larry Page, Arianna Huffington, and Ratan Tata among others. For more information, visit xprize.org
Kind Regards
Gitte Pedersen,
CEO Genomic Expression
